Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56


Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.

Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, Dangond F.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 11;5(5):e477. doi: 10.1212/NXI.0000000000000477. eCollection 2018 Sep.


Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.

Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875. [Epub ahead of print]


Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study.

Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, Dangond F, Giovannoni G.

Ther Adv Neurol Disord. 2018 Jan 23;11:1756285617753365. doi: 10.1177/1756285617753365. eCollection 2018.


Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials.

Traboulsee A, Li D, Tam R, Zhao G, Riddehough A, Fang J, Dangond F, Kappos L; PRISMS and SPECTRIMS Working Groups.

Mult Scler J Exp Transl Clin. 2017 Dec 8;3(4):2055217317745340. doi: 10.1177/2055217317745340. eCollection 2017 Oct-Dec.


Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.

Wray S, Hayward B, Dangond F, Singer B.

Expert Opin Drug Deliv. 2018 Feb;15(2):127-135. doi: 10.1080/17425247.2018.1407755. Epub 2017 Dec 5.


The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.

Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F.

Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317732802. doi: 10.1177/2055217317732802. eCollection 2017 Oct-Dec.


Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.

Mult Scler. 2018 Oct;24(12):1594-1604. doi: 10.1177/1352458517727603. Epub 2017 Sep 5.


Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.

Coyle PK, Reder AT, Freedman MS, Fang J, Dangond F.

J Neurol Sci. 2017 Aug 15;379:151-156. doi: 10.1016/j.jns.2017.05.052. Epub 2017 May 25.


Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.

De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP.

Mult Scler. 2018 Feb;24(2):222-226. doi: 10.1177/1352458517690269. Epub 2017 Jan 31.


Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.

Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Markovic-Plese S.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 12;2(6):e176. doi: 10.1212/NXI.0000000000000176. eCollection 2015 Dec.


Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.

Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S.

BMC Neurol. 2015 Nov 11;15:232. doi: 10.1186/s12883-015-0488-9.


A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis.

Zivadinov R, Dwyer M, Markovic-Plese S, Hayward B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Dangond F, Weinstock-Guttman B.

Ther Adv Neurol Disord. 2015 Mar;8(2):59-70. doi: 10.1177/1756285615572953.


Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly.

Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F.

J Neuroimmunol. 2015 Apr 15;281:44-50. doi: 10.1016/j.jneuroim.2015.03.002. Epub 2015 Mar 5.


A Real-World Assessment of Annual Multiple Sclerosis Prevalence and Disease-Modifying Drug Treatment Rates Using an Administrative Claims Database.

Phillips AL, Munsell MJ, Menzin J, Dangond F, Locklear JC.

Value Health. 2014 Nov;17(7):A392. doi: 10.1016/j.jval.2014.08.867. Epub 2014 Oct 26. No abstract available.


In vitro assessment of the biologic activity of interferon beta formulations used for the treatment of relapsing multiple sclerosis.

Scagnolari C, Selvaggi C, Di Biase E, Fraulo M, Dangond F, Antonelli G.

J Immunoassay Immunochem. 2014;35(3):288-99. doi: 10.1080/15321819.2013.848815.


Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.

Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B.

PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014.


Self-reported severity among patients with multiple sclerosis in the U.S. and its association with health outcomes.

Gupta S, Goren A, Phillips AL, Dangond F, Stewart M.

Mult Scler Relat Disord. 2014 Jan;3(1):78-88. doi: 10.1016/j.msard.2013.06.002. Epub 2013 Jun 27.


Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F.

BMC Neurol. 2013 Jul 11;13:80. doi: 10.1186/1471-2377-13-80.


Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation.

Huang H, Ito K, Dangond F, Dhib-Jalbut S.

J Neuroimmunol. 2013 May 15;258(1-2):27-31. doi: 10.1016/j.jneuroim.2013.02.010. Epub 2013 Mar 13.


Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.

Bandari D, Wynn D, Miller T, Singer B, Wray S, Bennett R, Hayward B, Dangond F; RebiQoL Study Group.

Mult Scler Relat Disord. 2013 Jan;2(1):45-56. doi: 10.1016/j.msard.2012.07.005. Epub 2012 Sep 25.


Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.

Singer B, Bandari D, Cascione M, LaGanke C, Huddlestone J, Bennett R, Dangond F; REFORMS Study Group.

BMC Neurol. 2012 Dec 6;12:154. doi: 10.1186/1471-2377-12-154.


Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.

Singer B, Wray S, Miller T, Cascione M, Gupta A, Pardo G, Watsky E, Hayward B, Mercer B, Dangond F.

Mult Scler Relat Disord. 2012 Apr;1(2):87-94. doi: 10.1016/j.msard.2011.11.002. Epub 2012 Jan 20.


Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.

Wray S, Armstrong R, Herrman C, Calkwood J, Cascione M, Watsky E, Hayward B, Mercer B, Dangond F.

Expert Opin Drug Deliv. 2011 Dec;8(12):1543-53. doi: 10.1517/17425247.2011.628656. Epub 2011 Oct 27.


Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.

Gray SG, Dangond F.

Epigenetics. 2006 Apr-Jun;1(2):67-75. Epub 2006 Mar 5. Review.


Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor.

Trujillo JR, Rogers R, Molina RM, Dangond F, McLane MF, Essex M, Brain JD.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5097-102. Epub 2007 Mar 14.


Histone deacetylase 3 represses HTLV-1 tax transcription.

Villanueva R, Iglesias AH, Camelo S, Sanin LC, Gray SG, Dangond F.

Oncol Rep. 2006 Sep;16(3):581-5.


Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.

Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH Jr, Ferrante RJ.

J Neurochem. 2005 Jun;93(5):1087-98. Erratum in: J Neurochem. 2006 Feb;96(3):908.


Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.

Gray SG, Iglesias AH, Lizcano F, Villanueva R, Camelo S, Jingu H, Teh BT, Koibuchi N, Chin WW, Kokkotou E, Dangond F.

J Biol Chem. 2005 Aug 5;280(31):28507-18. Epub 2005 May 31.


Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ, Dangond F.

J Neuroimmunol. 2005 Jul;164(1-2):10-21.


Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli.

Imitola J, Comabella M, Chandraker AK, Dangond F, Sayegh MH, Snyder EY, Khoury SJ.

Am J Pathol. 2004 May;164(5):1615-25.


Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells.

Iglesias AH, Camelo S, Hwang D, Villanueva R, Stephanopoulos G, Dangond F.

J Neuroimmunol. 2004 May;150(1-2):163-77.


Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter.

Dangond F, Hwang D, Camelo S, Pasinelli P, Frosch MP, Stephanopoulos G, Stephanopoulos G, Brown RH Jr, Gullans SR.

Physiol Genomics. 2004 Jan 15;16(2):229-39.


A compendium of gene expression in normal human tissues.

Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon W, Lee KF, Clark KE, Haverty P, Weng Z, Mutter GL, Frosch MP, MacDonald ME, Milford EL, Crum CP, Bueno R, Pratt RE, Mahadevappa M, Warrington JA, Stephanopoulos G, Stephanopoulos G, Gullans SR.

Physiol Genomics. 2001 Dec 21;7(2):97-104.


Differential expression of class I HDACs: roles of cell density and cell cycle.

Dangond F, Henriksson M, Zardo G, Caiafa P, Ekström TJ, Gray SG.

Int J Oncol. 2001 Oct;19(4):773-7.


Cell type-specific roles of histone deacetylase in TR ligand-independent transcriptional repression.

Lizcano F, Koibuchi N, Fukuda H, Dangond F, Chin WW.

Mol Cell Endocrinol. 2001 Feb 14;172(1-2):13-20.


Chips around the world: proceedings from the Nature Genetics microarray meeting.

Dangond F.

Physiol Genomics. 2000 Mar 13;2(2):53-8. No abstract available.


Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies.

Kiefer R, Dangond F, Mueller M, Toyka KV, Hafler DA, Hartung HP.

J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):362-8.


Cloning and expression of a murine histone deacetylase 3 (mHdac3) cDNA and mapping to a region of conserved synteny between murine chromosome 18 and human chromosome 5.

Dangond F, Foerznler D, Weremowicz S, Morton CC, Beier DR, Gullans SR.

Mol Cell Biol Res Commun. 1999 Aug;2(2):91-6.


Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells.

Dangond F, Hafler DA, Tong JK, Randall J, Kojima R, Utku N, Gullans SR.

Biochem Biophys Res Commun. 1998 Jan 26;242(3):648-52.


Constitutive expression of costimulatory molecules by human microglia and its relevance to CNS autoimmunity.

Dangond F, Windhagen A, Groves CJ, Hafler DA.

J Neuroimmunol. 1997 Jun;76(1-2):132-8.


Focal brain dysfunction in a 41-year old man with familial alternating hemiplegia.

Dangond F, Garada B, Murawski BJ, Rey-Casserly C, Holman BL, Mikati MA.

Eur Arch Psychiatry Clin Neurosci. 1997;247(1):35-41. Review.


Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions.

Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, Hafler DA.

J Exp Med. 1995 Dec 1;182(6):1985-96.


Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand.

Höllsberg P, Weber WE, Dangond F, Batra V, Sette A, Hafler DA.

Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4036-40.


Tropical spastic paraparesis on the Caribbean coast of Colombia.

Dangond F, Daza JS, Rosania A, Quin MJ, Zaninovic V, Chaplin B, Marlink R, Hafler DA.

Am J Trop Med Hyg. 1995 Feb;52(2):155-8.


Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody.

Hersh B, Dalmau J, Dangond F, Gultekin S, Geller E, Wen PY.

Neurology. 1994 Sep;44(9):1754-5.


Supplemental Content

Loading ...
Support Center